Methotrexate-Inadequate Response Study

For more information regarding BMS clinical trial participation, please visit
www.BMSStudyConnect.com

Inclusion Criteria:

- Subjects who are considered methotrexate inadequate responders

- 10 or more swollen joints (66 joint count) and 12 or more tender joints (68 joint
count)

Exclusion Criteria:

- Subjects who failed one or multiple anti-tumor necrosis factor (TNF) therapies

- Subjects who meet diagnostic criteria for any other rheumatic disease (e.g., lupus
erythematous)

- Subjects with active vasculitis of a major organ system (except for subcutaneous
rheumatoid nodules)

- Subjects with severe chronic or recurrent bacterial infections

- Subjects who have received treatment with rituximab

An Anti-TNF Failure Sub-study was initiated (recruited separately from Main study) using
the same treatment as the Main study in order to assess the immunogenicity and safety in
the Anti-TNF Failure population. The Sub-study terminated due to low recruitment and
participants were permitted to roll into the LT Open Label Period.